MA53489A - Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques - Google Patents
Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiquesInfo
- Publication number
- MA53489A MA53489A MA053489A MA53489A MA53489A MA 53489 A MA53489 A MA 53489A MA 053489 A MA053489 A MA 053489A MA 53489 A MA53489 A MA 53489A MA 53489 A MA53489 A MA 53489A
- Authority
- MA
- Morocco
- Prior art keywords
- therapeutic agents
- heteroaryl substituted
- sulphonamide compounds
- substituted sulphonamide
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725956P | 2018-08-31 | 2018-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53489A true MA53489A (fr) | 2021-12-08 |
Family
ID=67953876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053489A MA53489A (fr) | 2018-08-31 | 2019-08-29 | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10981905B2 (fr) |
| EP (1) | EP3844150A1 (fr) |
| JP (1) | JP7450606B2 (fr) |
| KR (1) | KR20210054510A (fr) |
| CN (1) | CN112638879B (fr) |
| AU (1) | AU2019331005B2 (fr) |
| BR (1) | BR112021000209A2 (fr) |
| CA (1) | CA3110853A1 (fr) |
| CL (1) | CL2021000443A1 (fr) |
| CO (1) | CO2021001433A2 (fr) |
| CR (1) | CR20210099A (fr) |
| DO (1) | DOP2021000031A (fr) |
| EA (1) | EA202190395A1 (fr) |
| EC (1) | ECSP21013035A (fr) |
| IL (1) | IL279810A (fr) |
| JO (1) | JOP20200337A1 (fr) |
| MA (1) | MA53489A (fr) |
| MX (1) | MX2021001380A (fr) |
| NI (1) | NI202100013A (fr) |
| PE (1) | PE20211066A1 (fr) |
| PH (1) | PH12021550381A1 (fr) |
| SG (1) | SG11202100109TA (fr) |
| TW (1) | TW202115018A (fr) |
| WO (1) | WO2020047323A1 (fr) |
| ZA (1) | ZA202100593B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019011121A2 (pt) | 2016-12-09 | 2019-10-01 | Xenon Pharmaceuticals Inc | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
| BR112020014428A2 (pt) | 2018-01-19 | 2020-12-01 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco |
| UA127024C2 (uk) | 2018-06-13 | 2023-03-15 | Ксенон Фармасьютікалз Інк. | Бензолсульфонамідні сполуки та їх застосування як терапевтичних агентів |
| US11964967B2 (en) | 2018-06-26 | 2024-04-23 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| CN112638879B (zh) | 2018-08-31 | 2024-06-18 | 泽农医药公司 | 杂芳基取代的磺酰胺化合物及其作为治疗剂的用途 |
| KR20210068422A (ko) | 2018-08-31 | 2021-06-09 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| JP2024508526A (ja) | 2021-03-04 | 2024-02-27 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| KR20240030592A (ko) * | 2022-08-31 | 2024-03-07 | 주식회사 아이엔테라퓨틱스 | 인비보 세포외 신경다발절 기록법을 이용한 전기생리학적 약효평가법 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5877193A (en) | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| IL132702A0 (en) | 1997-05-07 | 2001-03-19 | Galen Chemicals Ltd | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| CA2349832A1 (fr) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Derives de benzenesulfonamide et leur utilisation comme inhibiteurs de mek |
| AU5912500A (en) | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| MXPA05000130A (es) | 2002-06-27 | 2005-02-17 | Novo Nordisk As | Derivados de aril-carbonilo como agentes terapeuticos. |
| WO2004092123A2 (fr) | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibiteurs d'invasion fongique |
| WO2005000309A2 (fr) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Composes chimiques |
| EP1646628A1 (fr) | 2003-07-08 | 2006-04-19 | Novartis AG | Composes benzenesulfonylamino, et compositions pharmaceutiques contenant ces composes |
| EP2332912A1 (fr) | 2003-08-08 | 2011-06-15 | Vertex Pharmaceuticals Incorporated | Compositions utilisees comme inhibiteurs de canaux sodium voltage dependants |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| EP1888544A2 (fr) | 2004-12-17 | 2008-02-20 | Takeda San Diego, Inc. | Inhibiteurs des hydroxystéroides déshydrogénases |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| EP1937658A1 (fr) | 2005-10-06 | 2008-07-02 | Sanofi-Aventis | 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzène sulfonamides, procédés pour leur préparation et leur utilisation en tant que substances pharmaceutiques |
| RU2008129821A (ru) | 2005-12-21 | 2010-01-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероциклические производные в качестве модуляторов ионных каналов |
| EP2054385A2 (fr) | 2006-08-15 | 2009-05-06 | F. Hoffmann-Roche AG | Dérivés phényliques, de la pyridine et de la quinoléine |
| MX2009004019A (es) | 2006-10-19 | 2009-06-19 | Signal Pharm Llc | Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa. |
| JP5463285B2 (ja) | 2007-07-13 | 2014-04-09 | アイカジェン， インコーポレイテッド | ナトリウムチャネル阻害物質 |
| JP5460589B2 (ja) * | 2007-07-13 | 2014-04-02 | アイカジェン， インコーポレイテッド | ナトリウムチャネル阻害物質 |
| WO2009013171A2 (fr) | 2007-07-24 | 2009-01-29 | F. Hoffmann-La Roche Ag | Composés antiviraux hétérocycliques |
| US7935779B2 (en) | 2008-03-07 | 2011-05-03 | Great Eastern Resins Industrial Co., Ltd. | Synthesis of polyimides (PI) from poly-carbodiimides and dianhydrides by sequential self-repetitive reaction (SSRR) |
| NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
| RU2011103451A (ru) | 2008-07-01 | 2012-08-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероциклические производные в качестве модуляторов ионных каналов |
| GB0815947D0 (en) * | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
| WO2010029300A1 (fr) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Composés bis-aromatiques pour utilisation dans le traitement de l’inflammation |
| PE20142099A1 (es) | 2009-01-12 | 2014-12-13 | Icagen Inc | Derivados de sulfonamida |
| ES2533065T3 (es) | 2010-07-09 | 2015-04-07 | Pfizer Limited | Bencenosulfonamidas útiles como inhibidores de los canales de sodio |
| RU2563644C2 (ru) | 2010-08-20 | 2015-09-20 | Хатчисон Медифарма Лимитед | Пирролопиримидиновые соединения и их применения |
| CA2844799A1 (fr) | 2011-08-17 | 2013-02-21 | Amgen Inc. | Inhibiteurs de canal sodium heteroaryle |
| BR112014010197A2 (pt) | 2011-10-28 | 2017-04-18 | Merck Sharp & Dohme | composto, composição farmacêutica, método de tratamento de um distúrbio |
| CA2853439A1 (fr) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Composes de benzenesulfonamide et leur utilisation en tant qu'agents therapeutiques |
| US9481677B2 (en) | 2011-10-31 | 2016-11-01 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| WO2013122897A1 (fr) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline |
| EP3444249B1 (fr) | 2012-10-15 | 2020-05-13 | Daewoong Pharmaceutical Co., Ltd. | Bloqueurs de canal sodique, leur procédé de préparation et leur utilisation |
| BR112015009216A2 (pt) | 2012-10-26 | 2017-07-04 | Merck Sharp & Dohme | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica |
| BR112015008987A2 (pt) | 2012-10-26 | 2017-07-04 | Merck Sharp & Dohme | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica |
| TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
| CN105705501B (zh) | 2013-09-09 | 2019-04-19 | 百时美施贵宝公司 | RORγ调节剂 |
| KR20160054570A (ko) | 2013-09-10 | 2016-05-16 | 크로모셀 코포레이션 | 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자 |
| WO2015077905A1 (fr) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Composés de benzènesulfonamide à substitution bicycloamine ayant une activité sélective dans les canaux sodiques sensibles à la tension |
| WO2015099841A1 (fr) | 2013-12-23 | 2015-07-02 | Purdue Pharma L.P. | Indazoles et leur utilisation |
| CN106795149B (zh) | 2015-05-05 | 2019-09-24 | 上海海雁医药科技有限公司 | 双环取代的苯磺酰胺衍生物、其制法与医药上的用途 |
| KR20180096683A (ko) | 2015-12-18 | 2018-08-29 | 머크 샤프 앤드 돔 코포레이션 | 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 디아미노-알킬아미노-연결 아릴술폰아미드 화합물 |
| KR20180095598A (ko) | 2015-12-18 | 2018-08-27 | 머크 샤프 앤드 돔 코포레이션 | 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 히드록시알킬아민- 및 히드록시시클로알킬아민-치환된 디아민-아릴술폰아미드 화합물 |
| CN115054600B (zh) | 2016-05-03 | 2024-06-14 | 拜耳制药股份公司 | 芳族磺酰胺衍生物 |
| TN2018000385A1 (en) | 2016-05-20 | 2020-06-15 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| EP3541373B1 (fr) | 2016-11-17 | 2023-11-01 | Merck Sharp & Dohme LLC | Composés d'arylsulfonamide à liaisons diamino-alkylamino présentant une activité sélective dans les canaux sodiques sensibles à la tension |
| BR112019011121A2 (pt) * | 2016-12-09 | 2019-10-01 | Xenon Pharmaceuticals Inc | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| UA127024C2 (uk) | 2018-06-13 | 2023-03-15 | Ксенон Фармасьютікалз Інк. | Бензолсульфонамідні сполуки та їх застосування як терапевтичних агентів |
| CN112638898B (zh) | 2018-08-31 | 2024-04-09 | 泽农医药公司 | 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 |
| KR20210068422A (ko) | 2018-08-31 | 2021-06-09 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| CN112638879B (zh) | 2018-08-31 | 2024-06-18 | 泽农医药公司 | 杂芳基取代的磺酰胺化合物及其作为治疗剂的用途 |
-
2019
- 2019-08-29 CN CN201980055649.4A patent/CN112638879B/zh active Active
- 2019-08-29 KR KR1020217005599A patent/KR20210054510A/ko not_active Application Discontinuation
- 2019-08-29 CA CA3110853A patent/CA3110853A1/fr active Pending
- 2019-08-29 US US16/556,055 patent/US10981905B2/en active Active
- 2019-08-29 MA MA053489A patent/MA53489A/fr unknown
- 2019-08-29 WO PCT/US2019/048917 patent/WO2020047323A1/fr active Application Filing
- 2019-08-29 CR CR20210099A patent/CR20210099A/es unknown
- 2019-08-29 PE PE2021000164A patent/PE20211066A1/es unknown
- 2019-08-29 JP JP2021510434A patent/JP7450606B2/ja active Active
- 2019-08-29 EA EA202190395A patent/EA202190395A1/ru unknown
- 2019-08-29 SG SG11202100109TA patent/SG11202100109TA/en unknown
- 2019-08-29 MX MX2021001380A patent/MX2021001380A/es unknown
- 2019-08-29 AU AU2019331005A patent/AU2019331005B2/en active Active
- 2019-08-29 JO JOP/2020/0337A patent/JOP20200337A1/ar unknown
- 2019-08-29 BR BR112021000209-0A patent/BR112021000209A2/pt unknown
- 2019-08-29 EP EP19768963.1A patent/EP3844150A1/fr active Pending
-
2020
- 2020-02-07 TW TW109103817A patent/TW202115018A/zh unknown
- 2020-12-28 IL IL279810A patent/IL279810A/en unknown
-
2021
- 2021-01-27 ZA ZA2021/00593A patent/ZA202100593B/en unknown
- 2021-02-09 CO CONC2021/0001433A patent/CO2021001433A2/es unknown
- 2021-02-19 DO DO2021000031A patent/DOP2021000031A/es unknown
- 2021-02-22 CL CL2021000443A patent/CL2021000443A1/es unknown
- 2021-02-23 PH PH12021550381A patent/PH12021550381A1/en unknown
- 2021-02-24 US US17/183,401 patent/US11639351B2/en active Active
- 2021-02-25 EC ECSENADI202113035A patent/ECSP21013035A/es unknown
- 2021-02-25 NI NI202100013A patent/NI202100013A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020047323A1 (fr) | 2020-03-05 |
| ECSP21013035A (es) | 2021-03-31 |
| EA202190395A1 (ru) | 2021-06-15 |
| IL279810A (en) | 2021-03-01 |
| CN112638879A (zh) | 2021-04-09 |
| PE20211066A1 (es) | 2021-06-09 |
| PH12021550381A1 (en) | 2021-12-13 |
| US20200157089A1 (en) | 2020-05-21 |
| JP7450606B2 (ja) | 2024-03-15 |
| DOP2021000031A (es) | 2021-03-31 |
| JP2021535134A (ja) | 2021-12-16 |
| CO2021001433A2 (es) | 2021-05-10 |
| EP3844150A1 (fr) | 2021-07-07 |
| CR20210099A (es) | 2021-06-24 |
| SG11202100109TA (en) | 2021-02-25 |
| BR112021000209A2 (pt) | 2021-08-24 |
| AU2019331005B2 (en) | 2024-03-28 |
| KR20210054510A (ko) | 2021-05-13 |
| CN112638879B (zh) | 2024-06-18 |
| US20220348570A1 (en) | 2022-11-03 |
| AU2019331005A1 (en) | 2021-02-18 |
| US11639351B2 (en) | 2023-05-02 |
| CL2021000443A1 (es) | 2021-07-02 |
| MX2021001380A (es) | 2021-05-27 |
| US10981905B2 (en) | 2021-04-20 |
| JOP20200337A1 (ar) | 2020-12-24 |
| ZA202100593B (en) | 2023-10-25 |
| NI202100013A (es) | 2021-06-22 |
| CA3110853A1 (fr) | 2020-03-05 |
| TW202115018A (zh) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53489A (fr) | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'agents thérapeutiques | |
| MA48583A (fr) | Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA48765A (fr) | Cyanopyrrolidines substituées par sulfonamide ayant une activité en tant qu'inhibiteurs de dub | |
| MA52888A (fr) | Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques | |
| MA45377A (fr) | Composés hétérocycliques en tant qu'agents antibacteriens | |
| MA53488A (fr) | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques | |
| MA52421A (fr) | Composés pharmaceutiques | |
| MA50567A (fr) | Nouveaux composés de sulfonamide carboxamide | |
| MA56075A (fr) | Nouveaux composés de sulfonamide carboxamide | |
| MA46196A (fr) | Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal | |
| MA46091A (fr) | Composés biaryles utiles en tant qu'immunomodulateurs | |
| DK3986890T3 (da) | Benzisoxazol-sulfonamid-derivater | |
| MA51232A (fr) | Indane-amines utiles en tant qu'antagonistes de pd-l1 | |
| MA53170A (fr) | Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1 | |
| MA51224A (fr) | Composés de sulfonamide et leur utilisation | |
| MA56183A (fr) | Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b | |
| MA49017A (fr) | Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques | |
| MA52244A (fr) | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b | |
| MA53089A (fr) | Thiophènecarboxamides et analogues substitués utilisés en tant qu'agents antibactériens | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| DK3720433T3 (da) | Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom | |
| MA53924A (fr) | Modulateurs de l'expression d'apol1 | |
| MA54378A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine |